Estudio de cohortes sobre la carga socioeconómica de la enfermedad de Parkinson en Portugal

Reese, Jean; Winter, Y; Rosa, Mana Marques; Silva, A M Rodrigues E; Campenhausen, Sonja von; Freire, R.A.C.; Mateus, Céu; Balzer-Geldsetzer, M; Bötzel, Kai; Oertel, Wolfgang H.; Dodel, Richard; Sampaio, Camila Alves Machado

doi:10.33588/rn.5205.2010492

Cited by 5 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…27 Von Campenhausen et al (2011) 29 demonstrated that PD total costs of per semester, from the societal perspective, were lower in Eastern European countries (Russia: E2620; Czech Republic: E5510) as compared with most Western European countries (Austria: E9820; Germany: E8610; Italy: E8340). 27 Moreover, Reese et al (2011) 30 assessed the PD clinical condition and disease severity in relation to total costs, reporting that motor fluctuations were the main total costs predictor, with total cost for patients with motor fluctuations being 113.8% higher than for patients without motor fluctuations. 27 In our study, direct costs were higher in the HBMM group compared to the OBM group, although they did not reach statistical significance.…”

Section: Discussionmentioning

confidence: 99%

“…27 Moreover, Reese et al. (2011) 30 assessed the PD clinical condition and disease severity in relation to total costs, reporting that motor fluctuations were the main total costs predictor, with total cost for patients with motor fluctuations being 113.8% higher than for patients without motor fluctuations. 27 In our study, direct costs were higher in the HBMM group compared to the OBM group, although they did not reach statistical significance.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prospective study on cost-effectiveness of home-based motor assessment in Parkinson’s disease

et al. 2016

View full text Add to dashboard Cite

Introduction Treatment adjustments in Parkinson's disease (PD) are in part dependent on motor assessments. The aim of this study was to evaluate the cost-effectiveness of home-based motor monitoring plus standard in-office visits versus in-office visits alone in patients with advanced PD. Methods The procedures consisted of a prospective, one-year follow-up, randomized, case-control study. A total of 40 patients with advanced PD were randomized into two groups: 20 patients underwent home-based motor monitoring by using wireless motion sensor technology, while the other 20 patients had in-office visits. Motor and non-motor symptom severities, quality of life, neuropsychiatric symptoms, and comorbidities were assessed every four months. Direct costs were assessed using a standardized questionnaire. Cost-effectiveness was assessed using the incremental cost-effectiveness ratio (ICER). Results Both groups of PD patients were largely comparable in their clinical and demographic variables at baseline; however, there were more participants using levodopa-carbidopa intestinal gel in the home-based motor monitoring group. There was a trend for lower Unified Parkinson's Disease Rating Scale functional status (UPDRS II) scores in the patients monitored at home compared to the standard clinical follow-up ( p = 0.06). However, UPDRS parts I, III, IV and quality-adjusted life-years scores were similar between both groups. Home-based motor monitoring was cost-effective in terms of improvement of functional status, motor severity, and motor complications (UPDRS II, III; IV subscales), with an ICER/UPDRS ranging from €126.72 to €701.31, respectively. Discussion Home-based motor monitoring is a tool which collects cost-effective clinical information and helps augment health care for patients with advanced PD.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Prospective study on cost-effectiveness of home-based motor assessment in Parkinson’s disease

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Considering that resting tremor, bradykinesia, rigidity and postural instability are the main motor complications of PD and have a prevalence of up to 90% [ 27 ], this finding results paramount. Concurring with this statement, Reese et al (2011) [ 28 ] in their study with PD patients assessed the clinical condition, disease severity and related it to total costs, reporting that motor fluctuations were the main total costs predictor, being total cost for patients with motor fluctuations 113.8% higher than patients without motor fluctuations. In the same line, Cubo et al (2009) [ 25 ] in their study relating motor and non-motor symptoms with direct costs, also made a significant correlation between motor symptoms measured by SCOPA-Motor and direct costs.…”

Section: Discussionmentioning

confidence: 99%

Parkinson Symptoms and Health Related Quality of Life as Predictors of Costs: A Longitudinal Observational Study with Linear Mixed Model Analysis

et al. 2015

View full text Add to dashboard Cite

ObjectiveTo estimate the magnitude in which Parkinson’s disease (PD) symptoms and health- related quality of life (HRQoL) determined PD costs over a 4-year period.Materials and MethodsData collected during 3-month, each year, for 4 years, from the ELEP study, included sociodemographic, clinical and use of resources information. Costs were calculated yearly, as mean 3-month costs/patient and updated to Spanish €, 2012. Mixed linear models were performed to analyze total, direct and indirect costs based on symptoms and HRQoL.ResultsOne-hundred and seventy four patients were included. Mean (SD) age: 63 (11) years, mean (SD) disease duration: 8 (6) years. Ninety-three percent were HY I, II or III (mild or moderate disease). Forty-nine percent remained in the same stage during the study period. Clinical evaluation and HRQoL scales showed relatively slight changes over time, demonstrating a stable group overall. Mean (SD) PD total costs augmented 92.5%, from €2,082.17 (€2,889.86) in year 1 to €4,008.6 (€7,757.35) in year 4. Total, direct and indirect cost incremented 45.96%, 35.63%, and 69.69% for mild disease, respectively, whereas increased 166.52% for total, 55.68% for direct and 347.85% for indirect cost in patients with moderate PD. For severe patients, cost remained almost the same throughout the study. For each additional point in the SCOPA-Motor scale total costs increased €75.72 (p = 0.0174); for each additional point on SCOPA-Motor and the SCOPA-COG, direct costs incremented €49.21 (p = 0.0094) and €44.81 (p = 0.0404), respectively; and for each extra point on the pain scale, indirect costs increased €16.31 (p = 0.0228).ConclusionsPD is an expensive disease in Spain. Disease progression and severity as well as motor and cognitive dysfunctions are major drivers of costs increments. Therapeutic measures aimed at controlling progression and symptoms could help contain disease expenses.

show abstract

Cost-of-illness in multiple system atrophy and progressive supranuclear palsy

et al. 2011

Self Cite

View full text Add to dashboard Cite

Multiple system atrophy and progressive supranuclear palsy are disabling neurodegenerative disorders, also known as atypical parkinsonian syndromes. Currently, no health economic evaluations of these diseases are available. The objective of this study was to evaluate disease-related costs in German patients with multiple system atrophy and progressive supranuclear palsy and to identify cost-driving factors. We recruited 101 consecutive patients with multiple system atrophy (n = 54) and progressive supranuclear palsy (n = 47) in four German specialised movement disorder clinics. The health economic data were collected using comprehensive health economic questionnaires ("bottom-up" approach). Costs were calculated from the societal perspective in 2010 Euros. Independent cost-driving factors were identified in multiple regression analysis. The total semi-annual costs of atypical parkinsonian syndromes were EUR 16,670 (95% CI: 13,470-21,850). Direct costs accounted for 73% (inpatient care 31%, special equipment 24%, copayments of patients 21%, others 24%) and indirect costs for 27% of total costs. The economic burden imposed on patients by atypical parkinsonian syndromes accounted for 36% of their income. Independent cost-driving factors were younger age, disease severity, living without a partner and depression. The disease-related costs of atypical parkinsonian syndromes in Germany are high and above the costs reported for idiopathic Parkinson's disease. Disease-specific patterns of cost distributions in atypical parkinsonian syndromes and independent cost-drivers should be considered in future health economic evaluations and healthcare programs. The early diagnosis and treatment of depression in patients with atypical parkinsonian syndromes as well as programs aimed to improve social support will reduce disease-related costs.

show abstract

Estudio de cohortes sobre la carga socioeconómica de la enfermedad de Parkinson en Portugal

Cited by 5 publications

References 0 publications

Prospective study on cost-effectiveness of home-based motor assessment in Parkinson’s disease

Prospective study on cost-effectiveness of home-based motor assessment in Parkinson’s disease

Parkinson Symptoms and Health Related Quality of Life as Predictors of Costs: A Longitudinal Observational Study with Linear Mixed Model Analysis

Cost-of-illness in multiple system atrophy and progressive supranuclear palsy

Contact Info

Product

Resources

About